<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: <z:e sem="disease" ids="C0026654" disease_type="Disease or Syndrome" abbrv="MYMY|MYMY1">Moyamoya syndrome</z:e> is an uncommon <z:hpo ids='HP_0011010'>chronic</z:hpo> occlusive cerebrovascular disease in children </plain></SENT>
<SENT sid="1" pm="."><plain>The origin of <z:e sem="disease" ids="C0026654" disease_type="Disease or Syndrome" abbrv="MYMY|MYMY1">moyamoya syndrome</z:e> remains undetermined </plain></SENT>
<SENT sid="2" pm="."><plain>The role of the prothrombotic disorders contributing to its pathogenesis has not been completely elucidated </plain></SENT>
<SENT sid="3" pm="."><plain>The purpose of this study was to determine the frequency of prothrombotic disorders in a pediatric population with <z:e sem="disease" ids="C0026654" disease_type="Disease or Syndrome" abbrv="MYMY|MYMY1">moyamoya syndrome</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: From May 1992 to April 2000, a prospective study of 10 consecutive children with <z:e sem="disease" ids="C0026654" disease_type="Disease or Syndrome" abbrv="MYMY|MYMY1">moyamoya syndrome</z:e> was carried out at a single center </plain></SENT>
<SENT sid="5" pm="."><plain>Evaluation included the following assays: protein C, protein S, antithrombin, plasminogen, activated protein C resistance, factor V Leiden, and prothrombin gene mutations </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">Lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>, anticardiolipin antibodies, and anti-beta(2)-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I antibodies assays were also performed </plain></SENT>
<SENT sid="7" pm="."><plain>The clinical characteristics, underlying diseases, family history of <z:mp ids='MP_0005048'>thrombosis</z:mp>, radiological findings, treatment, and outcome were also recorded </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: In our series, prothrombotic disorders were detected in 4 patients (40%) </plain></SENT>
<SENT sid="9" pm="."><plain>Inherited <z:e sem="disease" ids="C0242666" disease_type="Disease or Syndrome" abbrv="">protein S deficiency</z:e> was found in 1 patient; <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> and anticardiolipin antibodies were detected in the remaining 3 patients </plain></SENT>
<SENT sid="10" pm="."><plain>One presented persistent <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> for 2.7 years until his <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>In the case of the other 2 patients, 1 has maintained <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> for 9 months, whereas the other has kept anticardiolipin/anti-beta(2)-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I antibodies for 10 months </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: We report the hemostatic data of the largest prospective pediatric study carried out at a single center in the western hemisphere </plain></SENT>
<SENT sid="13" pm="."><plain>In 4 patients (40%), a prothrombotic disorder was detected </plain></SENT>
<SENT sid="14" pm="."><plain>It is tempting to speculate that these hemostatic abnormalities may contribute to the pathogenesis of <z:e sem="disease" ids="C0026654" disease_type="Disease or Syndrome" abbrv="MYMY|MYMY1">moyamoya syndrome</z:e> in some of our patients </plain></SENT>
</text></document>